Skip to main content
. 2022 May 16;3(2):141–152. doi: 10.1093/ehjdh/ztac029

Table 2.

Participants characteristics of clinical validation cases

Clinical validation cases: N = 132
Age 75.0 ± 12.5
Male 72 (54.5%)
Hypertension 107 (81.1%)
Diabetes mellitus 33 (25.0%)
Dyslipidaemia 61 (46.2%)
Atrial fibrillation at enrolment) 41 (31.1%)
Heart rate (beats per minute) 74.4 ± 17.3
History of stroke/TIA 16 (12.1%)
History of myocardial infarction 19 (16.5%)
History of CABG 11 (8.3%)
NYHA classification I/II/III/IV 29/37/59/7
LVEF (%) 54.5 ± 13.1
Aortic stenosis (no/I/II/III) 34/28/28/42 (25.8%/21.2%/21.2%/31.8%)
Severe low-flow low-gradient AS 8
Aortic regurgitation (no/I/II/III) 63/46/23/0 (47.7%/34.8%/17.4%/0%)
Mitral stenosis (no/I/II/III) 117/13/2/0 (88.6%/9.8%/1.5%/0%)
Mitral regurgitation (no/I/II/III) 31/56/27/18 (23.5%/42.4%/20.5%/13.6%)
Tricuspid stenosis (no/I/II/III) 132/0/0/0 (100%/0%/0%/0%)
Tricuspid regurgitation (no/I/II/III) 39/77/14/2 (29.5%/58.3%/10.6%/1.5%)
PQ interval (ms) 180 ± 39
QRS duration (ms) 103 ± 26
QT interval (ms) 417 ± 46
QRS axis (ms) 16 ± 49

CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; TIA, transient ischaemic attack.